Condition: Pneumonia - Bacterial · Pseudomonas Aeruginosa Infection · Sponsor: MicrobiotiX Co., Ltd
The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MP101 administered in addition to standard antibiotic therapy in adult patients with acute Pseudomonas aeruginosa pneumonia. The study will also assess the pharmacokinetic and pharmacodynamic characteristics of MP101 and its antibacterial activity, including changes in P. aeruginosa burden in sputum and changes in susceptibility to MP101 and concomitant antibiotics.
This description comes directly from the study's public registry record.
Sangmin Lee, Director · 82-10-2807-7489 · smlee@microbiotix.net
Always discuss trial participation with your own doctor first.
| Severance Hospital | Seoul, Seodaemun-gu, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07492771